← Leaderboards
Pamela L. Zeitlin
Johns Hopkins University
$9,680,949
Attributed
$10,156,358
Total exposure
30
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $855.8K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$8,822,135 · 28
FDA$1,334,223 · 2
By mechanism
R01$6,130,460 · 4
T32$3,240,579 · 1
R56$426,793 · 1
P01$270,973 · 1
M01$87,553 · 23
Top collaborators
- Beth L Laube3 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Anna Mae Elizabeth Diehl$33,245,963
- Wayne Mitzner$20,452,046
- Lois A Brass-Ernst$0
- Sarah L Szanton$11,425,504
- Carole L Marcus$11,334,904
Others in their field
Top investigators on “Cystic Fibrosis”
- John F Engelhardt · University Of Iowa$42,933,706
- Michael R Knowles · University Of North Carolina Chapel Hill$30,250,682
- David A Stoltz · University Of Iowa$25,455,359
- Joseph Zabner · University Of Iowa$25,382,103
- Paul B McCray · University Of Iowa$25,146,293
- Richard C Boucher · University Of North Carolina Chapel Hill$24,890,955
Research focus
Cystic FibrosisChloride ChannelsClinical ResearchHuman SubjectLungButyratesHuman Therapy EvaluationGene MutationGene ExpressionClinical Trial Phase IGrantDrug Screening /EvaluationPseudomonas AeruginosaRespiratory EpitheliumCystic Fibrosis Transmembrane Conductance RegulatorChloride IonChloridesTranscription FactorIon TransportLung DiseasesBirthFundingInfectionChildhood
Grant awards (77)
Mechanism of Prostone Activation During CFTR Modulation$426,793
R56 · FY2022 · HL · contact PI
Ph 1-2 Study of Glycerolphenylbutyrate for Cystic Fibrosis IND 125,124 (12/5/15)$125,000
R01 · FY2019 · FD · contact PI
Defining the Pulmonary Attributes of Pre-symptomatic Lung Disease in Cystic Fibrosis$320,819
R01 · FY2017 · HL
Defining the Pulmonary Attributes of Pre-symptomatic Lung Disease in Cystic Fibrosis$315,000
R01 · FY2016 · HL
Ph 1-2 Study of Glycerolphenylbutyrate for Cystic Fibrosis IND 125,124 (12/5/15)$230,476
R01 · FY2016 · FD · contact PI
Defining the Pulmonary Attributes of Pre-symptomatic Lung Disease in Cystic Fibrosis$315,000
R01 · FY2015 · HL
Multidisciplinary Training Program in Pediatric Pulmonary$272,461
T32 · FY2015 · HL · contact PI
Phase 2 Study of Digitoxin for the Treatment of Cystic Fibrosis$289,603
R01 · FY2014 · FD · contact PI
Multidisciplinary Training Program in Pediatric Pulmonary$268,249
T32 · FY2014 · HL · contact PI
Multidisciplinary Training Program in Pediatric Pulmonary$212,301
T32 · FY2013 · HL · contact PI
Chloride Channels in Lung Development$405,900
R01 · FY2012 · HL · contact PI
Phase 2 study of digitoxin for cystic fibrosis - IND 70279$228,091
R01 · FY2012 · FD · contact PI
Multidisciplinary Training Program in Pediatric Pulmonary$190,140
T32 · FY2012 · HL · contact PI
Chloride Channels in Lung Development$410,000
R01 · FY2011 · HL · contact PI
Phase 2 study of digitoxin for cystic fibrosis - IND 70279$227,585
R01 · FY2011 · FD · contact PI
Multidisciplinary Training Program in Pediatric Pulmonary$218,224
T32 · FY2011 · HL · contact PI
Chloride Channels in Lung Development$410,000
R01 · FY2010 · HL · contact PI
Multidisciplinary Training Program in Pediatric Pulmonary$219,025
T32 · FY2010 · HL · contact PI
Chloride Channels in Lung Development$410,000
R01 · FY2009 · HL · contact PI
Multidisciplinary Training Program in Pediatric Pulmonary$216,938
T32 · FY2009 · HL · contact PI
Chloride Channels in Lung Development$67,043
R01 · FY2009 · HL · contact PI
Multidisciplinary Training Program in Pediatric Pulmonary$289,877
T32 · FY2008 · HL · contact PI
Phase 2 study of digitoxin for cystic fibrosis - IND 70279$233,468
R01 · FY2008 · FD · contact PI
Chloride Channels in Lung Development$310,055
R01 · FY2007 · HL · contact PI
Multidisciplinary Training Program in Pediatric Pulmona*$188,390
T32 · FY2007 · HL · contact PI
A PHASE 2 STUDY OF PTC124 FOR CYSTIC FIBROSIS$1,314
M01 · FY2007 · RR · contact PI
ASSESSMENT OF INDUCED SPUTUM$450
M01 · FY2007 · RR · contact PI
CAMP STIMULATED SWEAT RATE IN CYSTIC FIBROSIS$413
M01 · FY2007 · RR · contact PI
TRANSEPITHELIAL POTENTIAL DIFFERENCE IN PTS W/ VARIANTS OF CYSTIC FIBROSIS (CF)$338
M01 · FY2007 · RR · contact PI
Chloride Channels in Lung Development$319,316
R01 · FY2006 · HL · contact PI
Multidisciplinary Training Program in Pediatric Pulmona*$283,772
T32 · FY2006 · HL · contact PI
CF EXOCRINE PANCREATIC INSUFFICIENCY$13,289
M01 · FY2006 · RR · contact PI
ASSESSMENT OF INDUCED SPUTUM$5,617
M01 · FY2006 · RR · contact PI
TRANSEPITHELIAL POTENTIAL DIFFERENCE IN PTS W/ VARIANTS OF CF$822
M01 · FY2006 · RR · contact PI
STUDY OF AEROSOLIZED TGAAVCF FOR THE TREATMENT OF CF$548
M01 · FY2006 · RR · contact PI
CAMP STIMULATED SWEAT RATE IN CYSTIC FIBROSIS$411
M01 · FY2006 · RR · contact PI
DURATION OF TREATMENT EFFECT FOLLOWING ADMINISTRATION OF TOBI$274
M01 · FY2006 · RR · contact PI
Chloride Channels in Lung Development$327,000
R01 · FY2005 · HL
Multidisciplinary Training Program in Pediatric Pulmona*$307,290
T32 · FY2005 · HL
STUDY OF AEROSOLIZED TGAAVCF FOR THE TREATMENT OF CF$16,947
M01 · FY2005 · RR
CF EXOCRINE PANCREATIC INSUFFICIENCY$13,707
M01 · FY2005 · RR
STUDY OF ORAL SPI-8811 IN PATIENTS WITH CF$4,985
M01 · FY2005 · RR
TRANSEPITHELIAL POTENTIAL DIFFERENCE IN PTS W/ VARIANTS OF CF$3,489
M01 · FY2005 · RR
CAMP STIMULATED SWEAT RATE IN CYSTIC FIBROSIS$2,991
M01 · FY2005 · RR
28 DAY STUDY OF INS37217 INHALATION SOLUTION$997
M01 · FY2005 · RR
DURATION OF TREATMENT EFFECT FOLLOWING ADMINISTRATION OF TOBI$748
M01 · FY2005 · RR
Chloride Channels in Lung Development$327,000
R01 · FY2004 · HL
Multidisciplinary Training Program in Pediatric Pulmonary$294,058
T32 · FY2004 · HL
28 Day Study of INS37217 Inhalation Solution$7,677
M01 · FY2004 · RR
Multicenter Trial of Topical Aminoglycosides to Activa$5,171
M01 · FY2004 · RR
Duration of Treatment effect following administration of TOBI$2,037
M01 · FY2004 · RR
Study of Aerosolized tgAAVCF for the Treatment of CF$2,037
M01 · FY2004 · RR
Transepithelial Potential Difference in Pts. w/ ... Variants of ... CF$1,567
M01 · FY2004 · RR
Study of Oral SPI-8811 in Patients with CF$1,254
M01 · FY2004 · RR
cAMP Stimulated Sweat Rate in Cystic Fibrosis$470
M01 · FY2004 · RR
Multidisciplinary Training Program in Pediatric Pulmona*$279,854
T32 · FY2003 · HL
CHLORIDE CHANNELS IN LUNG DEVELOPMENT$286,125
R01 · FY2002 · HL
PHENYLBUTYRATE THERAPY FOR CYSTIC FIBROSIS$0
M01 · FY2002 · RR
PHENYLBUTRATE THERAPY FOR CYSTIC FIBROSIS$0
P01 · FY2002 · HL
PHASE I TRIAL OF INHALED DOSES OF IB 367 IN ADULT CF$0
M01 · FY2002 · RR
PHENYLBUTYRATE &MUCOCILIARY CLEARANCE IN CYSTIC FIBROSIS$0
M01 · FY2002 · RR
TRANSEPITHELIAL POTENTIAL DIFFERENCE MEASUREMENTS IN CF$0
M01 · FY2002 · RR
PHASE I DOSE ESCALATION AND SAFETY TRIAL OF PHENYLBUTYRATE THERAPY FOR CF$0
M01 · FY2002 · RR
CHLORIDE CHANNELS IN LUNG DEVELOPMENT$286,125
R01 · FY2001 · HL
PHASE I DOSE ESCALATION AND SAFETY TRIAL OF PHENYLBUTYRATE THERAPY FOR CF$0
M01 · FY2001 · RR
PHENYLBUTRATE THERAPY FOR CYSTIC FIBROSIS$0
P01 · FY2001 · HL
PHASE I TRIAL OF INHALED DOSES OF IB 367 IN ADULT CF$0
M01 · FY2001 · RR
PHENYLBUTYRATE &MUCOCILIARY CLEARANCE IN CYSTIC FIBROSIS$0
M01 · FY2001 · RR
TRANSEPITHELIAL POTENTIAL DIFFERENCE MEASUREMENTS IN CF$0
M01 · FY2001 · RR
PHENYLBUTYRATE THERAPY FOR CYSTIC FIBROSIS$0
M01 · FY2001 · RR
CHLORIDE CHANNELS IN LUNG DEVELOPMENT$286,854
R01 · FY2000 · HL
PHENYLBUTRATE THERAPY FOR CYSTIC FIBROSIS$270,973
P01 · FY2000 · HL
PHENYLBUTYRATE THERAPY FOR CYSTIC FIBROSIS$0
M01 · FY2000 · RR
PHENYLBUTYRATE &MUCOCILIARY CLEARANCE IN CYSTIC FIBROSIS$0
M01 · FY2000 · RR
TRANSEPITHELIAL POTENTIAL DIFFERENCE MEASUREMENTS IN CF$0
M01 · FY2000 · RR
PHASE I DOSE ESCALATION AND SAFETY TRIAL OF PHENYLBUTYRATE THERAPY FOR CF$0
M01 · FY2000 · RR
PHASE I TRIAL OF INHALED DOSES OF IB 367 IN ADULT CF$0
M01 · FY2000 · RR